drugset / Trial / NCT05667142
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Timeline
- Start
- 2023-02-14
- Primary completion
- 2027-04
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azetukalner | Small molecule | 15 mg | Oral |
| Subject | Azetukalner | Small molecule | 25 mg | Oral |